This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Novo Nordisk A/S
Drug Names(s): DegludecPlus, IDegAsp, Soluble insulin analogue combination (SIAC), NN5401, insulin degludec and insulin aspart
Description: NN5401 is a neutral, soluble, fixed-combination of long-acting basal insulin (degludec) and a fast-acting insulin, without a need for resuspension.
DegludecPlus (NN5401) will be provided in a new superior disposable pen and there will be no re-suspension step prior to use.
Ryzodeg 70/30 News
Additional information available to subscribers only: